NTLA
$101.03
Intellia Thera CS
($8.92)
(8.11%)
NTLA
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.89)
Revenue:  $10.31 Mil
Thursday
Feb 3
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NTLA reports earnings?
Beat
Meet
Miss

Where is NTLA's stock price going from here?
Up
Flat
Down
Stock chart of NTLA
Analysts
Summary of analysts' recommendations for NTLA
Score
Grade
Pivots
Resistance
$118.23
$114.12
$107.57

$103.46

Support
$96.91
$92.80
$86.25
Tweet
Growth
Description
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.